Skip to content

Migraine Study for Adolescents 12-17 years

NO LONGER ACCEPTING APPLICATIONS
Published on:
September 18, 2024
Sign-up Expiration:
Updated:
Topics:
Locations:

We are investigating high and low doses of IV Eptinezumab for preventative treatment of migraines in adolescents. There is an equal opportunity of receiving low dose Eptinezumab (50 or 100 mg), high dose Eptinezumab (150 or 300 mg), and placebo. The dosing is determined based on the subject’s weight, and the subject will only receive one infusion for the duration of the study.

View Additional Information
View Clinical Trial Attachment
Sign Up NowExpired - View Other Trials
ENDED